Weicai bile acid transporter inhibitor "goofice 5mg tablet" listed in Japan

On April 19, EA Pharmaceutical Co., Ltd (http://www.chemdrug.com/company/), a subsidiary of WaMu Co., Ltd focusing on gastrointestinal diseases, jointly announced with Takeda Pharmaceutical Co., Ltd that the bile acid transporter inhibitor "goofice 5mg tablet" (common name: elobixibat) Hydrate, R & D Code: ajg533) has been listed in the national medical insurance drug price catalog of Japan on April 18, 2018, and listed in Japan on April 19, 2018 EA Pharma obtained the license of gooffice tablet from Albireo AB company in Sweden About goofice goofice tablet (oral, once a day) is a drug that applies innovative mechanism of action to treat constipation (http://www.chemdrug.com/) By inhibiting the bile acid transporter that regulates bile acid reabsorption, goofice can increase the flow of bile acid in patients to colon, promote the secretion of more water, promote intestinal peristalsis, and achieve the effect of improving patients' natural defecation Goofice tablet is the first approved bile acid transporter inhibitor in the world Goofice tablet was developed by EA pharmaceutical and holding field EA pharmaceutical and chyta pharmaceutical will respectively distribute the product under the same brand name (http://www.chemdrug.com/invest/) Prior to that, EA pharmaceutical and Weicai have signed a cooperative promotion agreement, and will jointly publish specific information about the correct use of the product In a placebo-controlled, double-blind phase III clinical study conducted in Japan (this trial (http://www.chemdrug.com/sell/24/) As the basis of the approval of the drug market, spontaneous intestinal peristalsis (2) (primary end point), complete spontaneous intestinal peristalsis (3) (secondary end point), the first natural defecation time, stool characteristics and other aspects were significantly improved in the treatment group compared with the placebo group No serious adverse events were observed